Related Experiment Video
Updated: Jun 13, 2025
07:59
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
1.2K
Ranolazine Unveiled: Rediscovering an Old Solution in a New Light
Giulia Azzurra De Santis1, Tommaso De Ferrari1, Francesca Parisi2
1Cardiology Unit, Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy.
Journal of Clinical Medicine
|September 14, 2024
Summary
Ranolazine, an anti-anginal drug, shows antiarrhythmic effects by blocking sodium and potassium currents. Clinical studies suggest its potential in treating atrial and ventricular arrhythmias, often with other medications.
Area of Science:
- Cardiology
- Pharmacology
- Electrophysiology
Background:
- Ranolazine is an established anti-anginal agent.
- Emerging evidence suggests ranolazine possesses antiarrhythmic properties.
- Its mechanism involves inhibition of late sodium and potassium currents.
Purpose of the Study:
- To review the antiarrhythmic mechanisms of ranolazine.
- To evaluate the efficacy of ranolazine in cardiac arrhythmias.
- To explore its therapeutic potential based on clinical studies.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of ranolazine's electrophysiological effects.
- Synthesis of data on ranolazine's use in arrhythmias.
Main Results:
- Ranolazine inhibits late sodium and potassium currents.
- Studies indicate efficacy in atrial fibrillation and ventricular arrhythmias.
- Combination therapy with ranolazine shows promise.
Conclusions:
- Ranolazine exhibits significant antiarrhythmic potential.
- Its unique mechanism offers a novel approach to arrhythmia management.
- Further clinical investigation is warranted for broader application.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
464
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
464
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
933
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
933
01:26Heart Failure Drugs: Inotropic Agents
543
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
543
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
719
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
719
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
796
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
796